Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus

Ming Yang, Matthew Dent, Huafang Lai, Haiyan Sun, Qiang Chen

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

In this study, we described the generation and immunogenicity of the Zika Virus (ZIKV) envelope protein (E) domain III (DIII) as a protein subunit vaccine candidate. ZIKV EDIII (zEDIII) was rapidly produced in E. coli in inclusion bodies. ZIKV EDIII was solubilized, refolded and purified to >95% homogeneity with a one-step Ni2+ affinity chromatography process. Further analysis revealed that zEDIII was refolded properly and demonstrated specific binding to an anti-zEDIII monoclonal antibody that recognizes a zEDIII conformational epitope. Subcutaneous immunization of mice with 25 and 50μg of zEDIII was performed over a period of 11weeks. zEDIII evoked ZIKV-specific and neutralizing antibody response with titers that exceed the threshold that correlates with protective immunity against ZIKV. The antigen-specific IgG isotypes were predominantly IgG1 and splenocyte cultures from immunized mice secreted IFN-gamma, IL-4 and IL-6. Notably, zEDIII-elicited antibodies did not enhance the infection of dengue virus in Fc gamma receptor (FcγR)-expressing cells. This study provided a proof of principle for the further development of recombinant protein-based subunit vaccines against ZIKV.

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - 2017

Fingerprint

Viral Envelope Proteins
Tertiary Protein Structure
Immunization
Viruses
Zika virus
Subunit Vaccines
Protein Subunits
Immunoglobulin G
subunit vaccines
immunization
immune response
mice
proteins
IgG Receptors
Dengue Virus
Inclusion Bodies
Neutralizing Antibodies
Affinity Chromatography
Recombinant Proteins
Interleukin-4

Keywords

  • Antibody-dependent enhancement (ADE)
  • Antigen
  • Domain III (DIII)
  • Envelope protein
  • Neutralizing immunity
  • Vaccine
  • Zika virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. / Yang, Ming; Dent, Matthew; Lai, Huafang; Sun, Haiyan; Chen, Qiang.

In: Vaccine, 2017.

Research output: Contribution to journalArticle

Yang, Ming; Dent, Matthew; Lai, Huafang; Sun, Haiyan; Chen, Qiang / Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus.

In: Vaccine, 2017.

Research output: Contribution to journalArticle

@article{d817a43f027541e68bb4907b0ecb18de,
title = "Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus",
abstract = "In this study, we described the generation and immunogenicity of the Zika Virus (ZIKV) envelope protein (E) domain III (DIII) as a protein subunit vaccine candidate. ZIKV EDIII (zEDIII) was rapidly produced in E. coli in inclusion bodies. ZIKV EDIII was solubilized, refolded and purified to >95% homogeneity with a one-step Ni2+ affinity chromatography process. Further analysis revealed that zEDIII was refolded properly and demonstrated specific binding to an anti-zEDIII monoclonal antibody that recognizes a zEDIII conformational epitope. Subcutaneous immunization of mice with 25 and 50μg of zEDIII was performed over a period of 11weeks. zEDIII evoked ZIKV-specific and neutralizing antibody response with titers that exceed the threshold that correlates with protective immunity against ZIKV. The antigen-specific IgG isotypes were predominantly IgG1 and splenocyte cultures from immunized mice secreted IFN-gamma, IL-4 and IL-6. Notably, zEDIII-elicited antibodies did not enhance the infection of dengue virus in Fc gamma receptor (FcγR)-expressing cells. This study provided a proof of principle for the further development of recombinant protein-based subunit vaccines against ZIKV.",
keywords = "Antibody-dependent enhancement (ADE), Antigen, Domain III (DIII), Envelope protein, Neutralizing immunity, Vaccine, Zika virus",
author = "Ming Yang and Matthew Dent and Huafang Lai and Haiyan Sun and Qiang Chen",
year = "2017",
doi = "10.1016/j.vaccine.2017.04.052",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus

AU - Yang,Ming

AU - Dent,Matthew

AU - Lai,Huafang

AU - Sun,Haiyan

AU - Chen,Qiang

PY - 2017

Y1 - 2017

N2 - In this study, we described the generation and immunogenicity of the Zika Virus (ZIKV) envelope protein (E) domain III (DIII) as a protein subunit vaccine candidate. ZIKV EDIII (zEDIII) was rapidly produced in E. coli in inclusion bodies. ZIKV EDIII was solubilized, refolded and purified to >95% homogeneity with a one-step Ni2+ affinity chromatography process. Further analysis revealed that zEDIII was refolded properly and demonstrated specific binding to an anti-zEDIII monoclonal antibody that recognizes a zEDIII conformational epitope. Subcutaneous immunization of mice with 25 and 50μg of zEDIII was performed over a period of 11weeks. zEDIII evoked ZIKV-specific and neutralizing antibody response with titers that exceed the threshold that correlates with protective immunity against ZIKV. The antigen-specific IgG isotypes were predominantly IgG1 and splenocyte cultures from immunized mice secreted IFN-gamma, IL-4 and IL-6. Notably, zEDIII-elicited antibodies did not enhance the infection of dengue virus in Fc gamma receptor (FcγR)-expressing cells. This study provided a proof of principle for the further development of recombinant protein-based subunit vaccines against ZIKV.

AB - In this study, we described the generation and immunogenicity of the Zika Virus (ZIKV) envelope protein (E) domain III (DIII) as a protein subunit vaccine candidate. ZIKV EDIII (zEDIII) was rapidly produced in E. coli in inclusion bodies. ZIKV EDIII was solubilized, refolded and purified to >95% homogeneity with a one-step Ni2+ affinity chromatography process. Further analysis revealed that zEDIII was refolded properly and demonstrated specific binding to an anti-zEDIII monoclonal antibody that recognizes a zEDIII conformational epitope. Subcutaneous immunization of mice with 25 and 50μg of zEDIII was performed over a period of 11weeks. zEDIII evoked ZIKV-specific and neutralizing antibody response with titers that exceed the threshold that correlates with protective immunity against ZIKV. The antigen-specific IgG isotypes were predominantly IgG1 and splenocyte cultures from immunized mice secreted IFN-gamma, IL-4 and IL-6. Notably, zEDIII-elicited antibodies did not enhance the infection of dengue virus in Fc gamma receptor (FcγR)-expressing cells. This study provided a proof of principle for the further development of recombinant protein-based subunit vaccines against ZIKV.

KW - Antibody-dependent enhancement (ADE)

KW - Antigen

KW - Domain III (DIII)

KW - Envelope protein

KW - Neutralizing immunity

KW - Vaccine

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85021384039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021384039&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.04.052

DO - 10.1016/j.vaccine.2017.04.052

M3 - Article

JO - Vaccine

T2 - Vaccine

JF - Vaccine

SN - 0264-410X

ER -